PEDIATRICS· 2026Q1
Paraneoplastic Autoimmune Multiorgan Syndrome: Diagnostic Lessons for Pediatricians
- 0citations
- Q1SCImago
- 2026year
Short summary
A Janus kinase inhibitor was required to achieve remission of paraneoplastic autoimmune multiorgan syndrome in an 11-year-old boy, in addition to antitumor therapy for T-lymphoblastic lymphoma.
AI-generated from the title and abstract; the full text is not read.
Key points
- An 11-year-old boy presented with subacute erythroblastopenia, mucocutaneous manifestations, myositis, and hepatitis.
- Progressive lymphadenopathy led to the diagnosis of T-lymphoblastic lymphoma associated with paraneoplastic autoimmune multiorgan syndrome.
- Remission of the paraneoplastic syndrome required Janus kinase inhibitor in addition to antitumor therapy.
- Pediatricians should consider paraneoplastic origin in juvenile dermatomyositis with atypical features like hematologic and mucosal abnormalities.
AI-generated from the title and abstract; the full text is not read.
Abstract
We report the challenging diagnosis of an 11-year-old boy, presenting with subacute erythroblastopenia, followed by a multisystemic immune-mediated syndrome characterized by polymorphic mucocutaneous manifestations, associated with severe myositis related to a dermatomyositis-like phenotype and mild hepatitis. A progressive lymphadenopathy led to a delayed diagnosis of T-lymphoblastic lymphoma associated with paraneoplastic autoimmune multiorgan syndrome. To achieve remission of this paraneoplastic syndrome, Janus kinase inhibitor was required in addition to antitumor therapy. This case highlights several key points: (1) Pediatricians should consider a paraneoplastic origin when facing juvenile dermatomyositis with atypical features, such as hematologic and mucosal abnormalities; (2) in uncertain cases, early collaboration with oncologists is needed to optimize diagnostic and therapeutic strategies; (3) the choice of immunomodulatory therapy is critical in addition to antitumor therapy.
The authors' abstract, as published at the source. PEDIATRICS, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Epidemiology
EpidemiologyMedicine